FiercePharma

GlaxoSmithKline picks up NICE recommendation for Strimvelis, a €594,000 gene therapy

Despite being one of the most expensive drugs in the world, GlaxoSmithKline's gene therapy Strimvelis won the backing of the often stingy U.K. cost watchdogs to treat a rare disease called ADA-SCID, ...
FiercePharma

GSK inks money-back guarantee on $665K Strimvelis, blazing a trail for gene-therapy pricing

GlaxoSmithKline ($GSK) has struck a Strimvelis deal in Europe. The gene therapy for “bubble boy” disease, only the second of its kind, raised questions about ...
Medindia

GSK’s Gene Therapy, Strimvelis, for “Bubble Baby Disease” Gets NICE’s Approval

‘Costing 594,000 Euros, GlaxoSmithKline’s gene therapy Strimvelis is given only once and the effects are thought to be life-long.’ Strimvelis, gets NICE’s approval as a treatment option for ADA- ...
Nasdaq

FONDAZIONE TELETHON AND ORCHARD THERAPEUTICS COMPLETE TRANSFER OF MARKETING AUTHORIZATION OF STRIMVELIS FOR ADA-SCID IN EUROPE

Following a positive opinion from the EMA, the transfer of marketing authorization of Strimvelis from Orchard Therapeutics has been approved by the European Commission Fondazione Telethon will now be ...
London South East

GSK receives positive CHMP opinion for Strimvelis

GSK receives positive CHMP opinion in Europe for StrimvelisTM, the first gene therapy to treat very rare disease, ADA-SCID GlaxoSmithKline (LSE/NYSE: GSK) today announced that the Committee for ...